Cargando…

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study

BACKGROUND: Therapeutic modulation of TREM2-dependent microglial function might provide an additional strategy to slow the progression of Alzheimer's disease. Although studies in animal models suggest that TREM2 is protective against Alzheimer's pathology, its effect on tau pathology and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morenas-Rodríguez, Estrella, Li, Yan, Nuscher, Brigitte, Franzmeier, Nicolai, Xiong, Chengjie, Suárez-Calvet, Marc, Fagan, Anne M, Schultz, Stephanie, Gordon, Brian A, Benzinger, Tammie L S, Hassenstab, Jason, McDade, Eric, Feederle, Regina, Karch, Celeste M, Schlepckow, Kai, Morris, John C, Kleinberger, Gernot, Nellgard, Bengt, Vöglein, Jonathan, Blennow, Kaj, Zetterberg, Henrik, Ewers, Michael, Jucker, Mathias, Levin, Johannes, Bateman, Randall J, Haass, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926925/ https://www.ncbi.nlm.nih.gov/pubmed/35305339 http://dx.doi.org/10.1016/S1474-4422(22)00027-8

Ejemplares similares

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
por: Suárez-Calvet, Marc, et al.
Publicado: (2019)

Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

An Alzheimer‐associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function
por: Schlepckow, Kai, et al.
Publicado: (2017)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
por: Ewers, Michael, et al.
Publicado: (2020)

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline
por: Suárez‐Calvet, Marc, et al.
Publicado: (2018)

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
por: Xiang, Xianyuan, et al.
Publicado: (2016)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region
por: Schlepckow, Kai, et al.
Publicado: (2020)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
por: Suárez‐Calvet, Marc, et al.
Publicado: (2016)

γ‐Secretase cleavage of the Alzheimer risk factor TREM2 is determined by its intrinsic structural dynamics
por: Steiner, Andrea, et al.
Publicado: (2020)

Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk
por: Ali, Muhammad, et al.
Publicado: (2022)

Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease
por: Biel, Davina, et al.
Publicado: (2023)

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
por: Araque Caballero, Miguel Ángel, et al.
Publicado: (2018)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans
por: Xiang, Xianyuan, et al.
Publicado: (2018)

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
por: Schindler, Suzanne E., et al.
Publicado: (2021)

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)

Increase of TREM2 during Aging of an Alzheimer’s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis
por: Brendel, Matthias, et al.
Publicado: (2017)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
por: Hassenstab, Jason, et al.
Publicado: (2021)

Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020)

Microglia at Sites of Atrophy Restrict the Progression of Retinal Degeneration via Galectin-3 and Trem2 Interactions
por: Yu, Chen, et al.
Publicado: (2023)

Loss of TREM2 function increases amyloid seeding but reduces plaque associated ApoE
por: Parhizkar, Samira, et al.
Publicado: (2019)

Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency
por: Reifschneider, Anika, et al.
Publicado: (2022)

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2020)

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer disease
por: Tu, Jiaxin Cindy, et al.
Publicado: (2023)

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2
por: Gispert, Juan Domingo, et al.
Publicado: (2016)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease
por: Li, Fuhai, et al.
Publicado: (2021)

TREM2 expression in the brain and biological fluids in prion diseases
por: Diaz-Lucena, Daniela, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity
por: Rahmani, Farzaneh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mt8qibnbbb2pk4oih3li3rp024